Non-surgical, drug-free treatment delivers
what your patients need:

Immediate pain relief up to 90 days3

immediate pain relief

Less opioid use1

less opioid use
improved range of motion

Improved range of motion post-TKA4

Simple and safe—FDA-cleared

Simple and safe— FDA-cleared

In addition, iovera° has a broad indication and is commonly used to treat pain in other areas:

  • Hip
  • Rib
  • Shoulder
  • Foot and ankle
  • Spine
  • Head and neck
  • Mastectomy
niddle pin

Learn why iovera° is a compelling alternative to RFA.

Learn about the new Smart Tip

Learn how iovera° may help your patients

See clinical data in OA knee pain See results in pre-TKA
and post-TKA
lady reading
Let patients know you offer iovera° by registering for the Find a Doctor program today
Get registered

AAOS=American Academy of Orthopaedic Surgeons; CPG=clinical practice guidelines; FDA=US Food and Drug Administration; OA=osteoarthritis; TKA=total knee arthroplasty.

  • References:
  • 1. Dasa V et al. Knee. 2016;23(3):523-528.
  • 2. Data on file. Pacira BioSciences, Inc.; 2021.
  • 3. Radnovich R et al. Osteoarthritis Cartilage. 2017;25(8):1247-1256.
  • 4. Plessl D et al. J Am Acad Orthop Surg. 2020;28(21):e962-e968.
IFU View Instructions for Use
Additional Information

Pacira Pharmaceuticals, Inc.

A subsidiary of Pacira Biosciences, Inc.

10410 Science Center Drive, Building A

San Diego, CA 92121 U.S.A

Legal Disclaimer

Zimmer Biomet acquired the iovera° business from Pacira BioSciences, Inc. on 31 Jul 2026, obtaining contractual agreement for the development, manufacture, and commercialization of iovera°.

During the transition period under the applicable Transition Services Agreement, Pacira remains the legal manufacturer for applicable iovera° products and retains the related regulatory responsibilities.

Zimmer Biomet acts as a contracted service provider, performing certain design, manufacturing, quality, and post-market activities under Pacira's quality system and oversight until the transition is complete.